Bicara Therapeutics (BCAX) vs Immix Biopharma (IMMX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Immix Biopharma (IMMX) has outperformed Bicara Therapeutics (BCAX) over the past year, gaining 60.7% versus a loss of 53.2%. Immix Biopharma is the larger company by market cap ($583.3 million vs $560.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCAX | IMMX |
|---|---|---|
| Share price | $8.44 | $6.96 |
| Market cap | $560.31M | $583.33M |
| 1-day change | -7.46% | -1.14% |
| YTD return | -49.85% | +33.08% |
| 1-year return | -53.22% | +60.74% |
| EPS (TTM) | $-3.46 | $-0.83 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-137.95M | $-29.40M |
| 52-week high | $30.99 | $15.10 |
| 52-week low | $7.87 | $3.78 |
| Distance from 52-week high | -72.77% | -53.91% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +281.16% | +243.82% |
| Average volume | 1.20M | 1.45M |
| Shares outstanding | 66.39M | 83.81M |
| Employees | 103 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMMX has outperformed BCAX by 114.0 percentage points over the past year.
About Bicara Therapeutics
BCAX stock →Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 103 employees
About Immix Biopharma
IMMX stock →Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
BCAX vs IMMX FAQ
Which is bigger, Bicara Therapeutics or Immix Biopharma?
Immix Biopharma (IMMX) is larger, with a market capitalization of $583.33M compared with $560.31M for Bicara Therapeutics (BCAX).
Which stock has performed better over the past year, BCAX or IMMX?
IMMX returned +60.74% over the past 12 months, compared with -53.22% for BCAX (price return, excluding dividends). Past performance does not predict future results.
Are Bicara Therapeutics and Immix Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.